Interdisciplinary Program of Integrated OMICS for Biomedical Science, Yonsei University, Seoul 03722, Korea.
Department of Integrative Bioscience & Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Korea.
BMB Rep. 2022 Nov;55(11):553-558. doi: 10.5483/BMBRep.2022.55.11.110.
Hepatocellular carcinoma (HCC) is dangerous cancer that often evades early detection because it is asymptomatic and an effective detection method is lacking. For people with chronic liver inflammation who are at high risk of developing HCC, a sensitive detection method for HCC is needed. In a meta-analysis of The Cancer Genome Atlas pan-cancer methylation database, we identified a CpG island in the USP44 promoter that is methylated specifically in HCC. We developed methylation-sensitive high-resolution melting (MS-HRM) analysis to measure the methylation levels of the USP promoter in cell-free DNA isolated from patients. Our MS-HRM assay correctly identified 40% of patients with early-stage HCC, whereas the α-fetoprotein test, which is currently used to detect HCC, correctly identified only 25% of early-stage HCC patients. These results demonstrate that USP44 MS-HRM analysis is suitable for HCC surveillance. [BMB Reports 2022; 55(11): 553-558].
肝细胞癌 (HCC) 是一种危险的癌症，通常难以早期发现，因为它没有症状，且缺乏有效的检测方法。对于患有慢性肝脏炎症且有发生 HCC 高风险的人群，需要一种对 HCC 具有高灵敏度的检测方法。在癌症基因组图谱泛癌症甲基化数据库的一项荟萃分析中，我们在 USP44 启动子中鉴定出一个 CpG 岛，该岛在 HCC 中特异性甲基化。我们开发了甲基化敏感的高分辨率熔解曲线 (MS-HRM) 分析，以测量从患者分离的无细胞 DNA 中 USP 启动子的甲基化水平。我们的 MS-HRM 检测正确识别了 40%的早期 HCC 患者，而目前用于检测 HCC 的甲胎蛋白检测仅正确识别了 25%的早期 HCC 患者。这些结果表明，USP44 MS-HRM 分析适合 HCC 监测。[BMB 报告 2022;55(11):553-558]。
